×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Parkinsons disease | drug | rytary | carbidopa-levodopa

New Help for Parkinson's

Thursday, 08 January 2015 12:21 PM


Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease.
Impax's shares rose 12 pct at $34.67 in premarket trading.
The FDA had previously rejected the drug, citing issues with the company's manufacturing plant in Hayward, California. The agency later raised concerns about Impax's factory in Taiwan.
Rytary is a long-acting capsule formulation of carbidopa-levodopa, the standard of care for Parkinson's
 

© 2022 Thomson/Reuters. All rights reserved.


FDA-Approved-Drugs
Impax Laboratories Inc said the U.S. Food and Drug Administration had approved Rytary, its drug for treating Parkinson's disease.Impax's shares rose 12 pct at $34.67 in premarket trading. The FDA had previously rejected the drug, citing issues with the company's...
Parkinsons disease, drug, rytary, carbidopa-levodopa
70
2015-21-08
Thursday, 08 January 2015 12:21 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved